In the Democratic Republic of the Congo, a rare and deadly strain of Ebola — one for which no licensed vaccine exists — has claimed over two thousand lives across six provinces, confronting humanity once again with the ancient calculus of crisis and improvisation. Health authorities, unwilling to wait for perfect tools, have chosen to deploy Ervebo, a vaccine designed for a different viral strain, trusting that partial protection may be better than none at all. It is a decision born not of certainty but of necessity — a wager placed at the intersection of science, urgency, and the irreducible
Africa CDC Pushes Emergency Ebola Vaccine Deployment in DRC as Outbreak Spreads
The outbreak has caused 2,184 deaths among 4,665 confirmed cases across six provinces in DR Congo, with 965 recoveries recorded.
The current emergency risks becoming the deadliest the country has faced
Mark
Why use a vaccine designed for a different Ebola strain when there's no guarantee it will work?
Mimi
Because waiting for a perfectly matched vaccine could mean thousands more deaths. The Bundibugyo strain is rare—there's no licensed vaccine for it at all. Ervebo has a proven safety record and might offer some cross-protection. In an emergency this severe, that possibility is worth acting on.
Mark
What happens if the vaccine doesn't work as hoped?
Mimi
That's the gamble. But they're framing it as a learning opportunity too. Every dose deployed generates data about how the vaccine performs against this strain. That evidence could inform the response and future preparedness.
Mark
Who gets the vaccine first?
Mimi
The people most likely to encounter the virus—healthcare workers, burial teams, contacts of confirmed cases, community leaders. They're the ones keeping the outbreak from spreading further, so protecting them makes strategic sense.
Mark
Is 100,000 doses enough?
Mimi
It's a starting point. The request came from the DRC government itself, so it reflects what they think they need for the initial phase. But with 4,665 cases already confirmed and the outbreak still expanding, the real question is whether any vaccine supply can keep pace with transmission.
Mark
What does this say about global preparedness for rare diseases?
Mimi
That we're still reactive rather than proactive. The Bundibugyo strain exists. We knew it could cause outbreaks. But there was no vaccine ready for it. When crisis hits, we improvise with tools designed for something else and hope the science holds.
Il Polso
- A Bundibugyo Ebola outbreak declared in May has grown into one of the DRC's most dangerous health emergencies, with a fatality rate approaching 47% across 4,665 confirmed cases.
- The virus has breached six provinces and 54 health zones, with the northeast region of Ituri bearing the heaviest toll and new territories falling within its reach each week.
- No licensed vaccine exists for the Bundibugyo strain, leaving health officials to make an urgent, unconventional bet on Ervebo — a proven but strain-mismatched tool — as their primary line of defense.
- The DRC government has formally requested 100,000 doses from international vaccine reserves, a move Africa CDC Director-General Jean Kaseya called a critical turning point in the response.
- Deployment will target the most exposed — healthcare workers, burial teams, case contacts, and community leaders — while simultaneously generating scientific evidence on cross-strain vaccine effectiveness.
- World leaders including DRC President Tshisekedi, Africa CDC, and the WHO convened in Kinshasa to align on emergency measures, signaling that the international community is treating this as a crisis that cannot be allowed to deepen further.
In the Democratic Republic of the Congo, a rare and deadly strain of Ebola — one for which no licensed vaccine exists — has claimed over two thousand lives across six provinces, confronting humanity once again with the ancient calculus of crisis and improvisation. Health authorities, unwilling to wait for perfect tools, have chosen to deploy Ervebo, a vaccine designed for a different viral strain, trusting that partial protection may be better than none at all. It is a decision born not of certainty but of necessity — a wager placed at the intersection of science, urgency, and the irreducible value of human life.
The Democratic Republic of the Congo is confronting one of its most severe Ebola emergencies in recent memory, driven by the Bundibugyo ebolavirus — a rare strain for which no licensed vaccine exists. Since the outbreak was declared on May 15, the virus has spread to six provinces and 54 health zones, infecting 4,665 people and killing 2,184, a fatality rate of nearly 47 percent. Ituri province in the northeast remains the epicenter, while the most recent expansion into Bas-Uele's Buta territory underscores how far the outbreak has traveled.
Faced with a virus that outpaces available tools, the Africa Centers for Disease Control and Prevention has made an unconventional call: deploy Ervebo, a single-dose vaccine licensed specifically for the Zaire ebolavirus strain, in hopes it may offer some cross-protection against Bundibugyo. The DRC government has requested 100,000 doses from the International Coordinating Group on Vaccine Provision. Africa CDC Director-General Jean Kaseya, speaking at an online briefing, warned that the outbreak risks becoming the deadliest the country has ever faced and described the vaccine request as a meaningful step forward.
The logic behind the deployment is twofold. Ervebo carries a strong safety record and proven field performance in prior outbreaks, and while it has never been tested against Bundibugyo, the possibility of cross-strain protection — however uncertain — justifies its use given the scale of the crisis. The rollout will also serve as a live clinical study, generating evidence on how the vaccine performs against a strain it was never designed to target.
Priority access will go to those most exposed: healthcare workers, burial teams, community health workers, contacts of confirmed cases, and leaders in high-transmission areas. The strategy emerged from a high-level meeting in Kinshasa where President Felix Tshisekedi convened with Kaseya and WHO Director-General Tedros Adhanom Ghebreyesus. Whether this improvised defense can bend the outbreak's trajectory remains the defining question of the weeks ahead.
The Democratic Republic of the Congo is facing its most dangerous Ebola outbreak in years, and health authorities are taking an unconventional step to fight it. The Africa Centers for Disease Control and Prevention has called for the immediate deployment of Ervebo, a vaccine that was never designed for this particular strain of the virus, in hopes that it might offer some protection anyway.
The outbreak, caused by the Bundibugyo ebolavirus, was officially declared on May 15. It is a relatively uncommon variant—one for which no licensed vaccine currently exists. As of mid-August, the virus had spread across six provinces, infecting 4,665 people and killing 2,184. The case fatality rate stands at 46.8 percent. The disease has now reached 54 separate health zones across Bas-Uele, Haut-Uele, Ituri, North Kivu, South Kivu, and Tshopo provinces, with Ituri in the country's northeast remaining the hardest-hit region. The most recent expansion brought the outbreak to Buta in Bas-Uele Province, marking the sixth province to report cases. Among those infected, 965 have recovered.
Africa CDC Director-General Jean Kaseya framed the vaccine decision as essential to preventing catastrophe. "The current emergency risks becoming the deadliest the country has faced, and we cannot allow that trajectory to continue," he said during an online briefing. The DRC government has requested 100,000 doses of Ervebo from the International Coordinating Group on Vaccine Provision. Kaseya called this request "a big step" in the response effort.
Ervebo is a single-dose vaccine that has been prequalified by the World Health Organization and licensed specifically to protect against Ebola virus disease caused by the Zaire ebolavirus strain—a different variant than the one currently spreading. The vaccine has a proven track record of safety and successful deployment in previous Ebola outbreaks. But it has never been tested against Bundibugyo. The decision to deploy it anyway rests on the possibility that it might offer some cross-protection between strains, combined with the sheer urgency of the current crisis.
Kaseya explained that using Ervebo serves a dual purpose: it could help reduce severe illness and death while simultaneously generating scientific evidence about how the vaccine performs against a strain it was not designed to target. The doses would support clinical trials, protect frontline responders, and shield people at highest risk of infection.
The vaccine rollout will prioritize those most exposed to the virus. Healthcare workers, community health workers, burial teams, and the contacts of confirmed cases will be among the first to receive doses. Religious leaders and village leaders will also be included, as will people living or working in areas experiencing high transmission rates or facing repeated occupational exposure.
The decision emerged from a high-level crisis meeting held in Kinshasa the previous week, where DRC President Felix Tshisekedi met with Kaseya and World Health Organization Director-General Tedros Adhanom Ghebreyesus. The vaccine deployment was one of several immediate measures they agreed upon. As the outbreak continues to expand, the coming weeks will reveal whether this unconventional strategy can slow the spread of a virus for which the world has limited tools.
Citazioni salienti
The current emergency risks becoming the deadliest the country has faced, and we cannot allow that trajectory to continue.— Jean Kaseya, Africa CDC Director-General
Vuoi la storia completa?
Leggi l'originale su news.cgtn.com ↗
Health & Medicine